Comparing Ublituximab and Teriflunomide in Improving Fatigue in MS: Enrique Alvarez, MD, PhD

Ublituximab (Briumvi; TG Therapeutics), a recently approved therapy for relapsing forms of multiple sclerosis (MS), is an agent designed to target a unique epitope on CD20-expressing B-cells.